Sleep characteristics and HbA1c in patients with type 2 diabetes on glucose-lowering medication.
diabetes mellitus
obstructive
sleep
sleep apnea
type 2
Journal
BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
18
06
2020
revised:
28
07
2020
accepted:
04
08
2020
entrez:
2
9
2020
pubmed:
2
9
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
To examine the association of sleep duration, insomnia, and obstructive sleep apnea (OSA) with hemoglobin A1c (HbA1c) in a cohort of patients with type 2 diabetes (T2D) on glucose-lowering medications. 13 346 patients with T2D were included in the present analysis (mean age: 60.2 years; 56.6% were on antidiabetic drug monotherapy; 43.4% received at least two glucose-lowering medications). Sleep duration (short: ≤6 hours/day; normal: 7-8 hours/day; long: ≥9 hours/day) and frequency of insomnia symptoms were self-reported. The risk of OSA was considered high if at least two of the following conditions were fulfilled: regular snoring, frequent daytime sleepiness, and either obesity (≥30 kg/m Long sleep duration and a high risk for OSA were independently associated with higher HbA1c values (long vs normal sleep duration: +0.10% (95% CI 0.03 to 0.18); high vs low risk for OSA: +0.07% (95% CI 0.02 to 0.11), both p=0.004). No robust association was found of short sleep duration and frequent insomnia symptoms with HbA1c. Finally, a positive dose-response association between the number of sleep problems per subject (range: 0-3) and HbA1c was observed (β=0.04% (0.02 to 0.06), p=0.002). However, all significant associations were small. Screening for and treatment of sleep problems may help lower HbA1c levels in patients with T2D on glucose-lowering medications.
Identifiants
pubmed: 32868313
pii: 8/1/e001702
doi: 10.1136/bmjdrc-2020-001702
pmc: PMC7462247
pii:
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Sleep Med Rev. 2017 Feb;31:91-101
pubmed: 26944909
Sleep Med Rev. 2018 Aug;40:127-134
pubmed: 29233612
Ann Intern Med. 2004 Dec 7;141(11):846-50
pubmed: 15583226
Lancet. 1999 Oct 23;354(9188):1435-9
pubmed: 10543671
Am J Respir Crit Care Med. 2010 Mar 1;181(5):507-13
pubmed: 20019340
Am J Respir Crit Care Med. 2004 Jun 1;169(11):1231-7
pubmed: 15044204
World J Cardiol. 2014 Jul 26;6(7):517-30
pubmed: 25068013
Sleep. 2015 Feb 01;38(2):223-31
pubmed: 25325485
BMJ Open Diabetes Res Care. 2016 May 11;4(1):e000184
pubmed: 27239316
Psychoneuroendocrinology. 2013 Sep;38(9):1668-74
pubmed: 23428257
Diabetes Care. 2002 Apr;25(4):796-7
pubmed: 11919139
J Sleep Res. 2016 Feb;25(1):5-10
pubmed: 26361380
Ann Intern Med. 1999 Oct 5;131(7):485-91
pubmed: 10507956
Arch Intern Med. 2006 Sep 18;166(16):1768-74
pubmed: 16983057
Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):1044-9
pubmed: 18172212
Diabetes Care. 2009 Jul;32(7):1327-34
pubmed: 19502545
Diabetes Technol Ther. 2011 Sep;13(9):945-9
pubmed: 21714680
Ann N Y Acad Sci. 2014 Apr;1311:151-73
pubmed: 24628249
Epidemiol Psychiatr Sci. 2020 Apr 24;29:e118
pubmed: 32326995
Psychoneuroendocrinology. 2013 Oct;38(10):2075-82
pubmed: 23602132
Lancet Diabetes Endocrinol. 2018 Jan;6(1):60-68
pubmed: 28844889
BMJ Open. 2018 Mar 25;8(3):e019697
pubmed: 29581203
Diabetes Care. 2019 Jul;42(7):1326-1332
pubmed: 31048411
Sci Adv. 2018 Aug 22;4(8):eaar8590
pubmed: 30140739
PLoS One. 2016 Sep 15;11(9):e0162388
pubmed: 27631769
Diabetes Metab. 1996 Feb;22(1):37-42
pubmed: 8697294
Ann Intern Med. 2012 Oct 16;157(8):549-57
pubmed: 23070488
Diabetes Care. 2020 Jan;43(1):235-243
pubmed: 31719053